Abstracts tagged "randomized trials and vasculitis"

Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting
Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial
Christian Pagnoux¹, Thomas Quemeneur², Jacques Ninet³, Elodie Perrodeau⁴, Elizabeth Diot⁵, Xavier Kyndt⁶, Benoit de Wazières⁷, jean-Luc Reny⁸, Xavier Puéchal⁹, Pierre-Yves Leberruyer¹⁰, Olivier Lidove¹¹, Philippe Vanhille¹², Pascal Godmer¹³, Aimé Albath-Sadiki¹⁴, Boris Bienvenu¹⁵, Pascal Cohen¹⁶, Luc Mouthon¹⁷, Philippe Ravaud⁴, Loic Guillevin¹⁸ and French Vasculitis Study Group (FVSG)¹⁹, ¹Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, ²Internal medicine, CHR de Valenciennes, Valenciennes, France, ³Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ⁸Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, ⁹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁰Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, ¹¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ¹²Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, ¹⁵Médecine interne, CHU Côte de Nacre, CAEN, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁷Internal Medicine, Hopital Cochin, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France
Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].